Patents by Inventor Government Of The United States Of America, As
Government Of The United States Of America, As has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180237478Abstract: This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the MEW capsid polyprotein precursor into plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Inventor: The Government of the United States of America, as Represented by the Secretary, Department of Homeland Security
-
Publication number: 20140186551Abstract: A method of depositing solder material onto a substrate. The method includes adjusting a pressure within a vacuum chamber, the substrate being supported within the vacuum chamber. A temperature of the substrate is reduced such that the absolute temperature of the substrate is no greater than 20% of a melting temperature of the solder material The absolute temperature is maintained while solder material is deposited onto the substrate.Type: ApplicationFiled: January 3, 2013Publication date: July 3, 2014Applicant: Government of the United States of America, as represented by the Secretary of the Air ForceInventor: Government of the United States of America, as Represented by the Secretary of the Air Force
-
Publication number: 20140153327Abstract: A spin transport channel includes a dielectric layer contacting a conductive layer. The dielectric layer includes at least one of a tantalum oxide, hafnium oxide, titanium oxide, and nickel oxide. An intermediate spin layer contacts the dielectric layer. The intermediate spin layer includes at least one of copper and silver. The conductive layer is more electrochemically inert than the intermediate spin layer. A polarizer layer contacts the intermediate spin layer. The polarizer layer includes one of a nickel-iron based material, iron, and cobalt based material. The conductive layer and intermediate layer are disposed on opposite sides of the dielectric layer. The dielectric layer and the polarizer layer are disposed on opposite sides of the intermediate spin layer. The intermediate spin layer is arranged to form a conducting path through the dielectric layer configured to transport a plurality of electrons. Each of the plurality of electrons maintains a polarized electron spin.Type: ApplicationFiled: November 30, 2012Publication date: June 5, 2014Applicant: The National Institute of Standards and Technology Government of the United States of America, as ReInventor: The National Institute of Standards and Technology, Government of the United States of America, as R
-
Publication number: 20130225954Abstract: A device and methods for treating a subject with dysphagia or other neurological disease, neurological disorder, neurological injury, neurological impairment or neurodegenerative disease that affects voluntary motor control of the hyoid, pharynx, larynx, or oropharyngeal area is disclosed. A device of the invention generally comprises a vibrotactile stimulator for applying at least one stimulus to the outside surface of a subject's neck; a connector for attaching the vibrotactile stimulator to an outside surface of the subject's neck, and a switch control communicatively connected to the vibrotactile stimulator to selectively engage a manual stimulation module and/or automatic stimulation module. Stimulation of an outside surface of the throat area of a subject by a device of the invention stimulates a swallowing reflex in the subject.Type: ApplicationFiled: February 26, 2013Publication date: August 29, 2013Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTInventor: The Government of the United States of America, as represented by the Secretary, Department of Health
-
Publication number: 20130217352Abstract: A miniaturized, ruggedized, field-deployable Portable Exposure Assessment System (PEAS) is used to remotely monitor workers and provide real-time warning of exposure to musculoskeletal injury conditions via alarm and smart-phone transmission. The PEAS unit wirelessly acquires exposure data from sensors; conducts initial data analysis; triggers proximal and remote alarms; sends out text messages with abnormal data, GPS locations, and time stamps to a safety office; and saves data for more extensive assessment. Sensor technology is used in this field-deployable system to simultaneously measure and collect the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibration exposures. Wireless technology is used to set up wireless communication links between the sensors and a data logger and between the data logger and a smart phone with GPS, date/time stamp and text messaging capabilities.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of
-
Publication number: 20130217122Abstract: The present invention encompasses a method for expanding an antigen specific T cell from a population of cells. The method of the present invention comprises contacting a population of cells with an MHC restricted antigenic glypican-3 peptide. In some instances, the T cell is expanded using monocyte-derived dendritic cells and defined MHC restricted antigenic glypican-3 peptides. In one embodiment, high-affinity antigen-specific T-cell receptors (TCRs) can be cloned from the antigen specific T cell.Type: ApplicationFiled: February 21, 2013Publication date: August 22, 2013Applicants: The Trustees of the University of Pennsylvania, VeteranInventors: The Trustees of the University of Pennsylvania, Government of the United States of America as Represented by the Secretary of the Department of Veteran
-
Publication number: 20130202528Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137 (4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptpm (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: ApplicationFiled: April 16, 2013Publication date: August 8, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventor: The Government of the United States of America as Represented by the Secretary of the Departme
-
Publication number: 20130203799Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.Type: ApplicationFiled: April 4, 2013Publication date: August 8, 2013Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The University of North Carolina at Chapel Hill, The Regents of the University of Michigan, Progeria Research Foundation, Inc.Inventors: The Government of the United States of America as represented by the Secretary of the Department, Progeria Research Foundation, Inc., The Regents of the University of Michigan, The University of North Carolina at Chapel Hill
-
Publication number: 20130196936Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of Health and
-
Publication number: 20130198214Abstract: The present subject matter relates to a personalized weight management program incorporating dynamic feedback control using a validated mathematical model of metabolism and weight change. In general, the subject matter provides a system for repeated monitoring of one or more parameters such as, for example, body weight, physical activity, diet, eating behavior, or various other physiological and behavioral measurements, and using the parameter(s) to calculate an objective and personalized measure of adherence to a prescribed intervention, iteratively update mathematical model parameters, and adjust the prescribed intervention based on revised model predictions. Such a dynamic feedback control methodology can improve adherence to weight management interventions and result in greater weight loss and improved weight maintenance. The present subject matter also relates to a novel, cost-effective, weight management tool that could be widely disseminated through the internet and mobile computing platforms.Type: ApplicationFiled: January 30, 2013Publication date: August 1, 2013Inventor: The Government of the United State of America, as represented by the Secretary, Dept of Health and Human Services
-
Publication number: 20130195893Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: March 27, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of He
-
Publication number: 20130189264Abstract: This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.Type: ApplicationFiled: March 14, 2013Publication date: July 25, 2013Applicants: Department of Health and Human ServiceInventor: The Government of the United States of America as represented by the Secretary of the Department of Health and Hu
-
Publication number: 20130178692Abstract: A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicants: BRAINSWAY, INC., YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHInventors: BRAINSWAY, INC., GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPART, YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE
-
Publication number: 20130177984Abstract: This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.Type: ApplicationFiled: January 22, 2013Publication date: July 11, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventor: The Government of the United States of America as Represented by the Secretary of the Department of
-
Publication number: 20130149384Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: December 18, 2012Publication date: June 13, 2013Applicant: The Government of the United States of America, as represented by the Secretary, Department of HealtInventor: The Government of the United States of America, as represented by Secretary, Department of Health and Human Servi
-
Publication number: 20130149246Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: November 8, 2012Publication date: June 13, 2013Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: The Government of the United States of America,, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
-
Publication number: 20130143772Abstract: Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.Type: ApplicationFiled: November 12, 2012Publication date: June 6, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America a
-
Publication number: 20130136759Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.Type: ApplicationFiled: February 11, 2013Publication date: May 30, 2013Applicant: The Government of the United States of America being represented by the Secretary of the Depart.Inventor: The Government of the United States of America being represented by the Secretary of the Department
-
Publication number: 20130131542Abstract: Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test.Type: ApplicationFiled: January 14, 2013Publication date: May 23, 2013Applicants: The Government of the United State of America dba The Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Oregon Health & Science University, The Government of the United State of America dba The Department of Veterans Affairs
-
Publication number: 20130123349Abstract: The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.Type: ApplicationFiled: January 22, 2013Publication date: May 16, 2013Applicants: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Government Of The United States Of America, As Represented By The Secretary, The Regents Of The University Of California